FDA Requires NAION Warning on All GLP-1 Receptor Agonist Labels
FDA mandates NAION warning on all GLP-1 drugs after trial data showed elevated but rare risk. Overlap with common comorbidities limits causal clarity. EMA acted earlier; manufacturers face uniform labeling without differentiated findings.
The agency concluded a potential increased risk exists after examining 126 randomized trials with 134,253 patients that recorded 15 probable NAION events, ten on GLP-1 drugs. Rates reached 6.4 cases per 100,000 person-years versus 3.8 for comparators. A separate Sentinel analysis in type 2 diabetes patients showed 26-32 cases per 100,000 person-years, with statistically significant elevation only versus DPP-4 inhibitors.
Risk factors such as diabetes, hypertension, and sleep apnea overlap heavily with the patient population, and no causal mechanism emerged from animal studies. The EMA had already classified NAION as very rare for semaglutide in June 2025. Manufacturers noted the change applies class-wide without product-specific findings.
Prescribers must now weigh continuation against benefit when patients develop sudden unilateral vision loss. Future label revisions will depend on additional Sentinel and observational cohorts tracking incidence above background rates of 2.3-10.2 per 100,000 adults over 50.
Sources (2)
- [1]FDA Drug Safety Communication(https://www.fda.gov/drugs/drug-safety-and-availability)
- [2]Hathaway et al JAMA Ophthalmology 2024(https://jamanetwork.com/journals/jamaophthalmology)